Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RAD001) and Gemcitabine (GEM) in patients (pts) with advanced cancers.


3120 Background: Pre-clinical studies of E have shown dose-dependent inhibition of tumor growth, reduced tumor vascularity and potentiation of the activity of a number of cytotoxics, particularly GEM. This phase 1 study investigated E alone and then in combination with GEM. Initially, pts with advanced, refractory solid tumors were recruited to a dose… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.